-
1
-
-
52649180045
-
Evaluating time to cancer recurrence as a surrogate marker for survival from an information theory perspective
-
Alonso A, Molenberghs G. Evaluating time to cancer recurrence as a surrogate marker for survival from an information theory perspective. Stat Methods Med Res 2008;17:497-504.
-
(2008)
Stat Methods Med Res
, vol.17
, pp. 497-504
-
-
Alonso, A.1
Molenberghs, G.2
-
2
-
-
52649123777
-
Two simple approaches for validating a binary surrogate endpoint using data from multiple trials
-
Baker SG. Two simple approaches for validating a binary surrogate endpoint using data from multiple trials. Stat Methods Med Res 2008;17:505-14.
-
(2008)
Stat Methods Med Res
, vol.17
, pp. 505-514
-
-
Baker, S.G.1
-
3
-
-
52649101507
-
Surrogate endpoints: Wishful thinking or reality?
-
Burzykowski T. Surrogate endpoints: Wishful thinking or reality? Stat Methods Med Res 2008;17:463-6.
-
(2008)
Stat Methods Med Res
, vol.17
, pp. 463-466
-
-
Burzykowski, T.1
-
4
-
-
52649122745
-
Use of progression-free survival as a surrogate marker in oncology trials: Some regulatory issues
-
Chakravarty A, Sridhara R. Use of progression-free survival as a surrogate marker in oncology trials: Some regulatory issues. Stat Methods Med Res 2008;17:515-18.
-
(2008)
Stat Methods Med Res
, vol.17
, pp. 515-518
-
-
Chakravarty, A.1
Sridhara, R.2
-
5
-
-
52649149158
-
Surrogate endpoint validation: Statistical elegance versus clinical relevance
-
Green EM, Yothers G, Sargent DJ. Surrogate endpoint validation: Statistical elegance versus clinical relevance. Stat Methods Med Res 2008;17:477-86.
-
(2008)
Stat Methods Med Res
, vol.17
, pp. 477-486
-
-
Green, E.M.1
Yothers, G.2
Sargent, D.J.3
-
6
-
-
52649088322
-
Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective
-
Grothey A. Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective. Stat Methods Med Res 2008;17:529-35.
-
(2008)
Stat Methods Med Res
, vol.17
, pp. 529-535
-
-
Grothey, A.1
-
7
-
-
52649120836
-
Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer
-
Hughes MD. Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer. Stat Methods Med Res 2008;17:487-95.
-
(2008)
Stat Methods Med Res
, vol.17
, pp. 487-495
-
-
Hughes, M.D.1
-
8
-
-
52649094924
-
Surrogate endpoints for overall survival in advanced colorectal cancer: A clinician's perspective
-
Piedbois P, Croswell JM. Surrogate endpoints for overall survival in advanced colorectal cancer: A clinician's perspective. Stat Methods Med Res 2008;17:519-27.
-
(2008)
Stat Methods Med Res
, vol.17
, pp. 519-527
-
-
Piedbois, P.1
Croswell, J.M.2
-
9
-
-
52649148610
-
Individual-and trial-level surrogacy in colorectal cancer
-
Buyse M, Burzykowski T, Michiels S, et al. Individual-and trial-level surrogacy in colorectal cancer. Stat Methods Med Res 2008;17:467-75.
-
(2008)
Stat Methods Med Res
, vol.17
, pp. 467-475
-
-
Buyse, M.1
Burzykowski, T.2
Michiels, S.3
-
10
-
-
36849078044
-
Progression-free survival is a surrogate for survival in advanced colorectal cancer
-
DOI 10.1200/JCO.2007.11.8836
-
Buyse M, Burzykowski T, Carroll K, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007;25:5218-24. (Pubitemid 350232253)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.33
, pp. 5218-5224
-
-
Buyse, M.1
Burzykowski, T.2
Carroll, K.3
Michiels, S.4
Sargent, D.J.5
Miller, L.L.6
Elfring, G.L.7
Pignon, J.-P.8
Piedbois, P.9
-
11
-
-
42949145995
-
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer
-
Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 2008;26:1987-92.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1987-1992
-
-
Burzykowski, T.1
Buyse, M.2
Piccart-Gebhart, M.J.3
-
12
-
-
0042413836
-
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 Study Group
-
DOI 10.1200/JCO.2003.12.046
-
Fossella F, Pereira JR, Von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 2003;21:3016-24. (Pubitemid 46606280)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.16
, pp. 3016-3024
-
-
Fossella, F.1
Pereira, J.R.2
Von Pawel, J.3
Pluzanska, A.4
Gorbounova, V.5
Kaukel, E.6
Mattson, K.V.7
Ramlau, R.8
Szczesna, A.9
Fidias, P.10
Millward, M.11
Belani, C.P.12
-
13
-
-
0346796317
-
Docetaxel (D) versus vinorelbine-cisplatin (VC) as front-line treatment for patients with advanced non-small cell lung cancer (NSCLC) and with a normal level of serum alpha 1 acid glycoprotein (AAG): Additional data on quality of life (QOL). Preliminary results
-
[Abstract 2680]
-
Monnier A, Zatloukal P, Siffnerova H, et al. Docetaxel (D) versus vinorelbine-cisplatin (VC) as front-line treatment for patients with advanced non-small cell lung cancer (NSCLC) and with a normal level of serum alpha 1 acid glycoprotein (AAG): Additional data on quality of life (QOL). Preliminary results. Proc Am Soc Clin Oncol 2003 [Abstract 2680].
-
(2003)
Proc Am Soc Clin Oncol
-
-
Monnier, A.1
Zatloukal, P.2
Siffnerova, H.3
-
14
-
-
1342332364
-
Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: The Japanese taxotere lung cancer study group
-
DOI 10.1200/JCO.2004.06.114
-
Kubota K, Watanabe K, Kunitoh H, et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: The Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 2004;22:254-61. (Pubitemid 41095089)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.2
, pp. 254-261
-
-
Kubota, K.1
Watanabe, K.2
Kunitoh, H.3
Noda, K.4
Ichinose, Y.5
Katakami, N.6
Sugiura, T.7
Kawahara, M.8
Yokoyama, A.9
Yokota, S.10
Yoneda, S.11
Matsui, K.12
Kudo, S.13
Shibuya, M.14
Isobe, T.15
Segawa, Y.16
Nishiwaki, Y.17
Ohashi, Y.18
Niitani, H.19
-
15
-
-
19944427563
-
Sequential two-line strategy for stage IV non-small-cell lung cancer: Docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: Final results of a randomised phase II study
-
DOI 10.1093/annonc/mdi013
-
Douillard JY, Gervais R, Dabouis G, et al. Sequential two-line strategy for stage IV non-small-cell lung cancer: Docetaxel-cisplatin versus vinorelbine-cisplatin followed by crossover to single-agent docetaxel or vinorelbine at progression: Final results of a randomized phase II study. Ann Oncol 2005;16:81-9. (Pubitemid 40124483)
-
(2005)
Annals of Oncology
, vol.16
, Issue.1
, pp. 81-89
-
-
Douillard, J.-Y.1
Gervais, R.2
Dabouis, G.3
Le Groumellec, A.4
D'Arlhac, M.5
Spaeth, D.6
Coudert, B.7
Caillaud, D.8
Monnier, A.9
Clary, C.10
Maury, B.11
Mornet, M.12
Riviere, A.13
Clouet, P.14
Couteau, C.15
-
16
-
-
21144437547
-
Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III randomized trial
-
DOI 10.1200/JCO.2005.04.016
-
Georgoulias V, Ardavanis A, Tsiafaki X, et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III randomized trial. J Clin Oncol 2005;23:2937-45. (Pubitemid 46224112)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.13
, pp. 2937-2945
-
-
Georgoulias, V.1
Ardavanis, A.2
Tsiafaki, X.3
Agelidou, A.4
Mixalopoulou, P.5
Anagnostopoulou, O.6
Ziotopoulos, P.7
Toubis, M.8
Syrigos, K.9
Samaras, N.10
Polyzos, A.11
Christou, A.12
Kakolyris, S.13
Kouroussis, C.14
Androulakis, N.15
Samonis, G.16
Chatzidaki, D.17
-
17
-
-
20944436114
-
Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: A phase III study addressing the case for cisplatin
-
DOI 10.1093/annonc/mdi126
-
Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: A phase III study addressing the case for cisplatin. Ann Oncol 2005;16:602-10. (Pubitemid 40613327)
-
(2005)
Annals of Oncology
, vol.16
, Issue.4
, pp. 602-610
-
-
Pujol, J.-L.1
Breton, J.-L.2
Gervais, R.3
Rebattu, P.4
Depierre, A.5
Morere, J.-F.6
Milleron, B.7
Debieuvre, D.8
Castera, D.9
Souquet, P.-J.10
Moro-Sibilot, D.11
Lemarie, E.12
Kessler, R.13
Janicot, H.14
Braun, D.15
Spaeth, D.16
Quantin, X.17
Clary, C.18
-
18
-
-
33747080816
-
Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: Results of the West Japan Thoracic Oncology Group trial (WJTOG 9904)
-
DOI 10.1200/JCO.2006.06.1044
-
Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J ClinOncol 2006;24:3657-63. (Pubitemid 46630541)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.22
, pp. 3657-3663
-
-
Kudoh, S.1
Takeda, K.2
Nakagawa, K.3
Takada, M.4
Katakami, N.5
Matsui, K.6
Shinkai, T.7
Sawa, T.8
Goto, I.9
Semba, H.10
Seto, T.11
Ando, M.12
Satoh, T.13
Yoshimura, N.14
Negoro, S.15
Fukuoka, M.16
-
19
-
-
34848818029
-
Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: A meta-analysis of seven randomized clinical trials
-
DOI 10.1097/JTO.0b013e318153fa2b, PII 0124389420071000000011
-
Douillard JY, Laporte S, Fossella F, et al. Comparison of docetaxeland vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: A meta-analysis of seven randomized clinical trials. J Thorac Oncol 2007;2:939-46. (Pubitemid 47511598)
-
(2007)
Journal of Thoracic Oncology
, vol.2
, Issue.10
, pp. 939-946
-
-
Douillard, J.-Y.1
Laporte, S.2
Fossella, F.3
Georgoulias, V.4
Pujol, J.-L.5
Kubota, K.6
Monnier, A.7
Kudoh, S.8
Rubio, J.E.9
Cucherat, M.10
-
20
-
-
84877638088
-
Meta-analysis comparing docetaxel and vinca-alkaloids in the first-line treatment of NSCLC. Comparison of results based on individual patient data, study report data, and published data
-
Abstract 4
-
Laporte S, Buyse M, Baroux N, et al. Meta-analysis comparing docetaxel and vinca-alkaloids in the first-line treatment of NSCLC. Comparison of results based on individual patient data, study report data, and published data. Eur J Cancer Suppl. 2007;1:Abstract 4.
-
(2007)
Eur J Cancer Suppl.
, vol.1
-
-
Laporte, S.1
Buyse, M.2
Baroux, N.3
-
21
-
-
0035648331
-
Validation of surrogate endpoints in multiple randomized clinical trials with failure-time end points
-
Burzykowski T, Molenberghs G, Buyse M, et al. Validation of surrogate endpoints in multiple randomized clinical trials with failure-time end points. J R Stat Soc C 2001;50:405-22.
-
(2001)
J R Stat Soc C
, vol.50
, pp. 405-422
-
-
Burzykowski, T.1
Molenberghs, G.2
Buyse, M.3
-
22
-
-
33748751897
-
Surrogate threshold effect: An alternative measure for meta-analytic surrogate endpoint validation
-
DOI 10.1002/pst.207
-
Burzykowski T, Buyse M. Surrogate threshold effect: An alternative measure for meta-analytic surrogate endpoint validation. Pharm Stat 2006;5:173-86. (Pubitemid 44400217)
-
(2006)
Pharmaceutical Statistics
, vol.5
, Issue.3
, pp. 173-186
-
-
Burzykowski, T.1
Buyse, M.2
-
23
-
-
10444237218
-
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: A meta-analysis of survival outcomes
-
DOI 10.1016/j.lungcan.2004.10.014, PII S0169500204005409
-
Le Chevalier T, Scagliotti G, Natale R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: A meta-analysis of survival outcomes. Lung Cancer 2005; 47:69-80. (Pubitemid 39643243)
-
(2005)
Lung Cancer
, vol.47
, Issue.1
, pp. 69-80
-
-
Le Chevalier, T.1
Scagliotti, G.2
Natale, R.3
Danson, S.4
Rosell, R.5
Stahel, R.6
Thomas, P.7
Rudd, R.M.8
Vansteenkiste, J.9
Thatcher, N.10
Manegold, C.11
Pujol, J.-L.12
Van Zandwijk, N.13
Gridelli, C.14
Van Meerbeeck, J.P.15
Crino, L.16
Brown, A.17
FitzGerald, P.18
Aristides, M.19
Schiller, J.H.20
more..
-
24
-
-
70249130544
-
Duration of chemotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis of randomized trials
-
Soon YY, Stockler MR, Askie LM, et al. Duration of chemotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis of randomized trials. J Clin Oncol 2009;27:3277-83.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3277-3283
-
-
Soon, Y.Y.1
Stockler, M.R.2
Askie, L.M.3
-
25
-
-
71549143528
-
Detecting and overall survival benefit that is derived from progression-free survival
-
Broglio KR, Berry DA. Detecting and overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009;101:1642-9.
-
(2009)
J Natl Cancer Inst
, vol.101
, pp. 1642-9
-
-
Broglio, K.R.1
Berry, D.A.2
-
26
-
-
33747844588
-
Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: A meta-analysis
-
DOI 10.1016/S1470-2045(06)70800-2, PII S1470204506708002
-
Johnson KR, Ringland C, Stodkes BJ, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: A meta-analysis. Lancet Oncol 2006;7:741-6. (Pubitemid 44283658)
-
(2006)
Lancet Oncology
, vol.7
, Issue.9
, pp. 741-746
-
-
Johnson, K.R.1
Ringland, C.2
Stokes, B.J.3
Anthony, D.M.4
Freemantle, N.5
Irs, A.6
Hill, S.R.7
Ward, R.L.8
-
27
-
-
80051550048
-
Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis
-
Amit O, Mannino F, Stone AM, et al. Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis. Eur J Cancer 2011;47:1772-8.
-
(2011)
Eur J Cancer
, vol.47
, pp. 1772-1778
-
-
Amit, O.1
Mannino, F.2
Stone, A.M.3
-
28
-
-
78649478110
-
Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?
-
Soria JC, Massard C, Le Chevalier T. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol 2010;21:2324-32.
-
(2010)
Ann Oncol
, vol.21
, pp. 2324-2332
-
-
Soria, J.C.1
Massard, C.2
Le Chevalier, T.3
|